HUP0203751A2 - G-CSF Konjugátumok - Google Patents
G-CSF KonjugátumokInfo
- Publication number
- HUP0203751A2 HUP0203751A2 HU0203751A HUP0203751A HUP0203751A2 HU P0203751 A2 HUP0203751 A2 HU P0203751A2 HU 0203751 A HU0203751 A HU 0203751A HU P0203751 A HUP0203751 A HU P0203751A HU P0203751 A2 HUP0203751 A2 HU P0203751A2
- Authority
- HU
- Hungary
- Prior art keywords
- conjugates
- polypeptides
- csf
- therapy
- activity
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000002364 leukopenia Diseases 0.000 abstract 1
- 231100001022 leukopenia Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A találmány tárgyát új, granulocita-kolóniát serkentő faktor (G-CSF)aktivitást mutató polipeptidek, G-CSF aktivitást mutató polipeptid ésnem polipeptid természetű fragmentum közötti konjugátumok, apolipeptideket kódoló nukleotidszekvenciát, azokat tartalmazóexpressziós vektorok és gazdasejtek, ilyen polipeptidek vagykonjugátumok előállítására szolgáló eljárások, és ilyen polipeptidekés konjugátumok terápiában - előnyösen leukopenia kezelésére irányulóterápiában - történő alkalmazása képezi. Ó
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000024 | 2000-01-10 | ||
DKPA200000341 | 2000-03-02 | ||
DKPA200000943 | 2000-06-16 | ||
PCT/DK2001/000011 WO2001051510A2 (en) | 2000-01-10 | 2001-01-09 | G-csf conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203751A2 true HUP0203751A2 (hu) | 2003-07-28 |
HUP0203751A3 HUP0203751A3 (en) | 2005-01-28 |
Family
ID=27222334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203751A HUP0203751A3 (en) | 2000-01-10 | 2001-01-09 | G-csf conjugates |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP2133098A1 (hu) |
JP (1) | JP2003519478A (hu) |
KR (1) | KR100773323B1 (hu) |
CN (1) | CN1188172C (hu) |
AR (1) | AR027509A1 (hu) |
AT (1) | ATE435033T1 (hu) |
AU (2) | AU782580B2 (hu) |
BR (1) | BR0107561A (hu) |
CA (1) | CA2395713C (hu) |
CZ (1) | CZ20022727A3 (hu) |
DE (1) | DE60139110D1 (hu) |
DK (1) | DK1250154T3 (hu) |
ES (1) | ES2327606T3 (hu) |
HK (1) | HK1051964A1 (hu) |
HU (1) | HUP0203751A3 (hu) |
IL (2) | IL150153A0 (hu) |
MX (1) | MXPA02006795A (hu) |
NO (1) | NO20023315L (hu) |
NZ (1) | NZ520261A (hu) |
SK (1) | SK11672002A3 (hu) |
WO (1) | WO2001051510A2 (hu) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0107561A (pt) * | 2000-01-10 | 2002-11-19 | Maxygen Holdings Ltd | Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos |
US6831158B2 (en) | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
GB0022877D0 (en) * | 2000-09-18 | 2000-11-01 | Isis Innovation | Analogues |
MXPA04000231A (es) | 2001-07-11 | 2004-05-04 | Maxygen Holdings Ltd | Conjugados del factor de estimulacion de colonias de granulocitos. |
PT2279755E (pt) * | 2001-10-10 | 2014-06-04 | Ratiopharm Gmbh | Remodelação e glicoconjugação do factor de crescimento de fibroblastos (fgf) |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
GB0130720D0 (en) * | 2001-12-21 | 2002-02-06 | Serono Internat S A | Proteins |
KR100508358B1 (ko) * | 2002-03-20 | 2005-08-17 | 주식회사 바이오폴리메드 | 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 g-csf의 제조 방법 |
JP4326470B2 (ja) * | 2002-08-31 | 2009-09-09 | シージェイチェイルジェダンコーポレーション | 糖鎖化ヒト顆粒球コロニー刺激因子同種体 |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
AU2004221824B2 (en) | 2003-03-14 | 2009-08-27 | Ratiopharm Gmbh | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
AU2004238146A1 (en) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or remedy for diseases accompanied by tissue destruction |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US7220407B2 (en) | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP1765853B1 (en) | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-linked glycosylation of G-CSF peptides |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
ES2566670T3 (es) | 2004-10-29 | 2016-04-14 | Ratiopharm Gmbh | Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF) |
CA2586365A1 (en) | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
JP2006137678A (ja) * | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | インターロイキン−2組成物 |
AU2006203792B2 (en) | 2005-01-10 | 2011-11-03 | Ratiopharm Gmbh | Glycopegylated Granulocyte Colony Stimulating Factor |
WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US7381805B2 (en) * | 2005-06-01 | 2008-06-03 | Maxygen Holdings, Ltd. | Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF |
KR100694994B1 (ko) | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
KR100735784B1 (ko) | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
WO2008124406A2 (en) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Methods of treatment using glycopegylated g-csf |
WO2008147534A1 (en) * | 2007-05-22 | 2008-12-04 | Maxygen Holdings Ltd. | Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
PT2197919E (pt) | 2007-08-27 | 2014-07-17 | Ratiopharm Gmbh | Formulação líquida de conjugado de g-csf |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
ES2523030T3 (es) | 2008-02-18 | 2014-11-20 | Jiangsu Hengrui Medicine Co., Ltd. | Un conjugado del G-CSF modificado por un polímero hidrosoluble |
PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
WO2010001414A1 (en) * | 2008-07-03 | 2010-01-07 | Lupin Limited | Expression of heterologous proteins in bacterial system using a gm-csf fusion tag |
WO2010037855A1 (en) | 2008-10-02 | 2010-04-08 | Octagene Gmbh | Improved processing of recombinant human g-csf |
EP2874646A4 (en) * | 2012-04-17 | 2016-07-06 | Univ Aarhus | SORCS1 FOR USE IN THE TREATMENT OF ADIPOSITAS AND OVERWEIGHT |
KR101623906B1 (ko) | 2014-07-23 | 2016-05-24 | 주식회사 이큐스앤자루 | 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
CN107916257B (zh) * | 2018-01-09 | 2020-07-28 | 华南理工大学 | T1脂肪酶突变体和应用 |
IL291906A (en) * | 2019-10-08 | 2022-06-01 | Zymeworks Inc | Different extracellular region of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines that bind it |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4470461A (en) | 1982-09-30 | 1984-09-11 | Phillips Petroleum Company | Organic nitro compounds as cosurfactants in enhanced oil recovery processes |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
ATE93541T1 (de) | 1985-07-03 | 1993-09-15 | Genencor Int | Hybride polypeptide und verfahren zu deren herstellung. |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
EP0243465A1 (en) | 1985-10-25 | 1987-11-04 | Vivian L. Mackay | Method of using bar1 for secreting foreign proteins |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
US5714581A (en) | 1986-12-23 | 1998-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5362853A (en) | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5214132A (en) | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
JP2928287B2 (ja) * | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
WO1990005783A1 (en) | 1988-11-18 | 1990-05-31 | Cetus Corporation | Insect signal peptide mediated secretion of recombinant proteins |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0893439B1 (en) | 1989-04-19 | 2005-07-27 | Enzon, Inc. | A process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide |
ATE136315T1 (de) | 1989-05-27 | 1996-04-15 | Sumitomo Pharma | Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine. |
US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
US5023328A (en) | 1989-08-04 | 1991-06-11 | The Texas A&M University System | Lepidopteran AKH signal sequence |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5492821A (en) | 1990-11-14 | 1996-02-20 | Cargill, Inc. | Stabilized polyacrylic saccharide protein conjugates |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
WO1992016555A1 (en) | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
IL104734A0 (en) | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
WO1995013090A1 (en) | 1993-11-10 | 1995-05-18 | Enzon, Inc. | Improved interferon polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
PT726778E (pt) | 1994-02-08 | 2001-12-28 | Amgen Inc | Sistema de administracao oral de proteinas g-csf modificadas quimicamente |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
DE69532884T2 (de) | 1994-03-07 | 2004-09-02 | Nektar Therapeutics, San Carlos | Verfahren und mittel zur verabreichung von insulin über die lunge |
US5473034A (en) | 1994-03-18 | 1995-12-05 | Hyogo Prefectural Government | Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
WO1995033490A1 (en) | 1994-06-02 | 1995-12-14 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
AU2705895A (en) | 1994-06-30 | 1996-01-25 | Novo Nordisk Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
CA2204726A1 (en) | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
AU6655496A (en) | 1995-08-11 | 1997-03-12 | Novo Nordisk A/S | Method for preparing polypeptide variants |
US6100070A (en) | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
RU2199347C2 (ru) | 1996-08-02 | 2003-02-27 | Орто-Макнейл Фармасьютикал, Инк. | Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером |
US6077543A (en) | 1996-12-31 | 2000-06-20 | Inhale Therapeutic Systems | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
EP0954589A1 (en) | 1997-01-24 | 1999-11-10 | Novo Nordisk A/S | Synthetic leader peptide sequences |
JP2001508783A (ja) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF |
RO121474B1 (ro) | 1997-06-06 | 2007-06-29 | Kyowa Hakko Kogyo Co., Ltd. | Polipeptide modificate chimic |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
SK286217B6 (sk) | 1998-04-28 | 2008-05-06 | Laboratoires Serono Sa | Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom |
WO2000042560A2 (en) | 1999-01-19 | 2000-07-20 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides |
BR0107561A (pt) * | 2000-01-10 | 2002-11-19 | Maxygen Holdings Ltd | Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos |
-
2001
- 2001-01-09 BR BR0107561-6A patent/BR0107561A/pt not_active IP Right Cessation
- 2001-01-09 WO PCT/DK2001/000011 patent/WO2001051510A2/en active IP Right Grant
- 2001-01-09 HU HU0203751A patent/HUP0203751A3/hu unknown
- 2001-01-09 AU AU23533/01A patent/AU782580B2/en not_active Ceased
- 2001-01-09 NZ NZ520261A patent/NZ520261A/en not_active IP Right Cessation
- 2001-01-09 IL IL15015301A patent/IL150153A0/xx unknown
- 2001-01-09 EP EP09075142A patent/EP2133098A1/en not_active Withdrawn
- 2001-01-09 KR KR1020027008944A patent/KR100773323B1/ko not_active IP Right Cessation
- 2001-01-09 JP JP2001551094A patent/JP2003519478A/ja active Pending
- 2001-01-09 AT AT01900105T patent/ATE435033T1/de not_active IP Right Cessation
- 2001-01-09 CA CA2395713A patent/CA2395713C/en not_active Expired - Fee Related
- 2001-01-09 CN CNB018035906A patent/CN1188172C/zh not_active Expired - Fee Related
- 2001-01-09 ES ES01900105T patent/ES2327606T3/es not_active Expired - Lifetime
- 2001-01-09 DK DK01900105T patent/DK1250154T3/da active
- 2001-01-09 DE DE60139110T patent/DE60139110D1/de not_active Expired - Lifetime
- 2001-01-09 CZ CZ20022727A patent/CZ20022727A3/cs unknown
- 2001-01-09 SK SK1167-2002A patent/SK11672002A3/sk not_active Application Discontinuation
- 2001-01-09 MX MXPA02006795A patent/MXPA02006795A/es active IP Right Grant
- 2001-01-09 EP EP01900105A patent/EP1250154B1/en not_active Expired - Lifetime
- 2001-01-09 AR ARP010100090A patent/AR027509A1/es active IP Right Grant
-
2002
- 2002-06-11 IL IL150153A patent/IL150153A/en not_active IP Right Cessation
- 2002-07-09 NO NO20023315A patent/NO20023315L/no not_active Application Discontinuation
-
2003
- 2003-04-23 HK HK03102880.6A patent/HK1051964A1/xx not_active IP Right Cessation
-
2005
- 2005-10-12 AU AU2005222524A patent/AU2005222524B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NO20023315D0 (no) | 2002-07-09 |
EP2133098A1 (en) | 2009-12-16 |
AU782580B2 (en) | 2005-08-11 |
AU2353301A (en) | 2001-07-24 |
EP1250154A2 (en) | 2002-10-23 |
BR0107561A (pt) | 2002-11-19 |
JP2003519478A (ja) | 2003-06-24 |
KR20020079778A (ko) | 2002-10-19 |
IL150153A0 (en) | 2002-12-01 |
ES2327606T3 (es) | 2009-11-02 |
CN1404401A (zh) | 2003-03-19 |
WO2001051510A3 (en) | 2002-03-21 |
CN1188172C (zh) | 2005-02-09 |
DE60139110D1 (de) | 2009-08-13 |
AR027509A1 (es) | 2003-04-02 |
WO2001051510A2 (en) | 2001-07-19 |
DK1250154T3 (da) | 2009-08-17 |
NZ520261A (en) | 2003-10-31 |
SK11672002A3 (sk) | 2002-12-03 |
NO20023315L (no) | 2002-09-05 |
AU2005222524B2 (en) | 2008-12-11 |
AU2005222524A1 (en) | 2005-11-10 |
MXPA02006795A (es) | 2005-04-19 |
CA2395713A1 (en) | 2001-07-19 |
ATE435033T1 (de) | 2009-07-15 |
KR100773323B1 (ko) | 2007-11-05 |
HUP0203751A3 (en) | 2005-01-28 |
HK1051964A1 (en) | 2003-08-29 |
CZ20022727A3 (cs) | 2002-11-13 |
IL150153A (en) | 2009-12-24 |
CA2395713C (en) | 2012-04-10 |
EP1250154B1 (en) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203751A2 (hu) | G-CSF Konjugátumok | |
HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
NZ271756A (en) | Human macrophage inflammatory proteins and coding sequences, their production and use | |
HK1080517A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
HUP0203035A2 (hu) | Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások | |
MXPA02002384A (es) | Polipeptidos similares al factor de crecimiento de fibroblastos. | |
ATE386538T1 (de) | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden | |
PT737207E (pt) | Inibidores de plasmina humana derivados de dominios kunitz | |
HUP0301246A2 (hu) | Humán véralvadási faktor VII változatai | |
AU1724795A (en) | Human tissue inhibitor of metalloproteinase-4 | |
DE69837273D1 (de) | Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen | |
CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
MX9602977A (es) | Proteinas que reparan la mala union de adn humano. | |
TR200003347T2 (tr) | Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler | |
HUP0300054A1 (hu) | Daganatspecifikus állati fehérjék | |
DE60118359D1 (de) | Humanische pellino-polypeptide | |
IL174645A0 (en) | MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES | |
EP1401858A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS COATING THEREOF AND METHOD OF USE | |
EP1432726A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS CODED FOR THEM, AND METHOD OF USE | |
EP1539985A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE | |
BR0008917A (pt) | Compostos | |
EP1399537A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF USE | |
DE69935213D1 (de) | Basb019 proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen | |
GB0120022D0 (en) | Conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |